Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Founded in 1966, Afric Phar is a privately owned Moroccan pharmaceutical company that has evolved into a fully integrated operation, spanning production, marketing, sales and distribution. As one of the first pharmaceutical companies established entirely by Moroccan pharmacists, it has built a strong reputation within the local market. Specializing in the import, manufacturing and distribution of generic drugs, Afric Phar serves a wide range of therapeutic areas. The company has also expanded its product portfolio and market reach through strategic partnerships with leading European and multinational laboratories under licensing agreements.
Pharma Capital, part of the Sefrioui group, is a Moroccan joint-stock company. The company focuses on investments in the pharmaceutical sector and was established as a dedicated vehicle to execute this specific investment strategy.
The Chaoui family, founders and owners of Afric Phar, have been instrumental to the company’s success, guiding it through decades of growth and innovation in Morocco’s pharmaceutical sector.
Oaklins’ team in Morocco acted as the sell-side advisor for a group of the selling shareholders, responsible for structuring, executing and negotiating the transaction.
相关交易
Generali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
更多信息Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
更多信息Xiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
更多信息